Hector Castro (Colombia), 2018-21
Hector Castro is a Doctor in Medicine and Surgery. He has an MSc in Health Policy, Planning and Financing, from the London School of Hygiene & Tropical Medicine (LSHTM) and a joint degree with the London School of Economics & Political Science (LSE). He specialized in Health Management and had a previous MSc in Occupational Health (Public Health Branch). He is a Doctor in Public Health and Policy/Health Economics from the University of London (LSHTM), and former Takemi Postdoctoral Fellow at the T.H. Chan Harvard School of Public Health.
Dr. Castro has over 18 years of broad professional experience, as Chief Officer, Technical Advisor, Director and Manager in strategic planning, quality assurance, health, safety and environment for pharmaceutical, health insurance and non-governmental organizations. His main focus of work has been on health systems` strengthening in areas such as quality assurance, assessment, strategic purchasing and provision of healthcare technologies (including medicines, devices and procedures).
Dr. Castro has more than ten years of experience as an international consultant in health care access, health economics, health policy, priority setting, health technology assessment (HTA) and health systems´ reform. He is also familiar with and has relevant experience in health systems and markets in low and middle-income countries (LMICs). His previous working experience includes the US, United Kingdom, Colombia, Ecuador, Ukraine, Belarus, Thailand, Peru, Costa Rica, Brazil, Mexico, Chile, Turkey and Tunisia. He also has experience as a researcher and lecturer for undergraduate and post graduate students in ivy league institutions in Latin America, the US and United Kingdom.
Dr. Castro is a former funding Chief Executive Director of the HTA Institute of Colombia (IETS) and Director of Medicines and Technologies at the Ministry of Health and Social Protection of Colombia. Currently, he is Senior Technical Director of Pharmaceutical Economics and Financing at MSH. Starting June 2018 and until 2021, he will serve at the Board of Directors of the Health Technology Assessment International (HTAi), one of the most prominent international networks in the field of HTA.
Kalipso Chalkidou (United Kingdom), 2016-19
Kalipso Chalkidou is the Director of the Global Health and Development Group at the Institute of Global Health Innovation, Imperial College London, helping governments build technical and institutional capacity for improving the value for money of their healthcare investment. She is interested in how local information, local expertise and local institutions can drive scientific and legitimate healthcare resource allocation decisions whilst improving patient outcomes. She has been involved in the Chinese rural health reform and also in national health reform projects in the USA, India, Colombia, Turkey and the Middle East, working with the World Bank, PAHO, DFID and the Inter-American Development Bank as well as national governments. Between 2008 and 2016 she founded and ran NICE International, a non-profit group within the UK’s National Institute for Health and Care Excellence.
YingYao Chen (China), 2016-2019
Yingyao Chen is the Associate Dean and Professor of Health Services at the School of Public Health, Fudan University, and Director of the Key Lab of Health Technology Assessment (KLHTA) (National Health and Family Planning Commission) at Fudan University, Shanghai, China.
He received his Bachelor of Medicine at Shanghai Medical University in 1991 and Master of Public Health at Shanghai Medical University in 1997, and earned his Ph.D. in Management at Fudan University in 2006. He was a visiting scholar at the University of California, Los Angeles, 1999-2001.
His academic interests focus on health technology assessment, knowledge translation, health policy, health economics, and hospital management. He was a PI of several projects funded by the World Health Organization, World Bank, China Medical Board, National Health and Family Planning Commission (formerly Ministry of Health), Ministry of Science and Technology, National Natural Science Foundation of China, and provincial health and medical insurance authorities. He has published 150 papers, of which 100 in Chinese and 10 in English with first or corresponding authorship. He is the editor-in-chief of two books: Health Services Evaluation and Disease Burdens of Main Birth Defects and Economic Evaluation of Their Preventive Strategies in China. He is a co-author of 14 books. He is also one of the core members to draft the Guideline for Health Technology Assessment in China.
Karen Facey (United Kingdom), 2017-20
Karen Facey is a Chartered Statistician, Honorary Member of the Faculty of Public Health, and Fellow of the Royal Society of Medicine. Following a statistical career in the pharmaceutical industry and medicines regulation, Karen was founding Chief Executive of the first national Health Technology Assessment (HTA) Agency in Scotland, which established the Scottish Medicines Consortium. She now works internationally as a consultant with all stakeholders, advising on matters relating to HTA and patient involvement, with a particular interest in Managed Entry Agreements and rare diseases.
During her consultancy, Karen has served for eight years as a Non-Executive Director on the governance board of a regional healthcare payer/provider in Scotland. For eleven years, she led government committees revising the funding formulae for NHSScotland resource allocation. She was Chair of the HTAi Global Policy Forum for three years. In 2014, she was named by the British Science Council as one of the top 100 practicing scientists in the UK for her work in HTA and patient wellbeing.
Karen is now a member of the Scottish Health Technologies Group, which provides national appraisal advice on non-medicine technologies. She is an Honorary Research Fellow at the Usher Institute of Population Health Sciences and Informatics at the University of Edinburgh, where she is involved in research related to the use of administrative health data to optimize medicine usage.
Karen has been committed to HTAi since its inception. She was on the founding board of HTAi and established the HTAi Interest Groups for Patient and Citizen Involvement in HTA (PCIG) and Assessment of Vaccination Programmes. She was Chair of the HTAi Policy Forum from 2008-2010 and has served as its scientific secretary. She was Co-Chair of the International Scientific Programme Committee for the conference in South Korea. She has represented HTAi on various collaborative efforts with patient groups, including EUPATI, EURORDIS symposium and ISPOR roundtable. Karen is on the editorial board of several journals including IJTAHC and has led themed editions with the HTAi PCIG. She was invited by Springer to develop a book about Patient Involvement in HTA with members of PCIG and this will be published in summer 2017.
Karen sits on the HTAi Policy Forum Coordinating Committee and the Interest Group steering committee.
Rabia Kahveci (Turkey), 2017-20
Rabia Kahveci is the founding Chair of ANHTA (Ankara Numune Training and Research Hospital HTA Unit) which is the only hospital based HTA initiative in Turkey. She is co-director of International Affairs Office and Deputy Clinical Director and Associate Professor in Family Medicine Department in the same hospital.
She is a medical doctor with specialization in family medicine, has a master’s degree in health technology assessment and management (SWOT analysis for establishing an HTA program in Turkey), and an associate degree in management of health institutions.
She worked in the Ministry of Health, Directorate of Pharmaceuticals and Pharmacies prior to her hospital experience and conducted HTA studies at the national level. She was a member of the national committee on reimbursement of the social security, where she promoted HTA as an aid to policy decisions. During that time she was also actively involved in the organization of several national and international events related to HTA, including HTA training programs. She has dedicated her last 10 years for improving evidence-based health care and health technology assessment in Turkey. Besides organizations, she also published articles and reports and is well known for her international collaborative efforts.
Kahveci is the founding and current Chair of the Turkish Evidence Based Medicine (EBM) Association; via this NGO she has been an active promoter of evidence based policy making in the country. The EBM Association has been active in organizing trainings in HTA to help improve human resources. The EBM Association is also a collaborating partner in EUnetHTA JA(2). The Association organized International Meeting for HTA- Emerging Countries in 2009, in Ankara, which hosted 23 countries’ leaders on HTA. She is also leading National HTA Forums every year since then.
Kahveci is also the contact person for ANHTA in AdHopHTA, an EU Project for “Adopting Hospital based HTA in EU” that runs from 2013-2015. She is a member of HTAi IG on Hospital based HTA and chair of HTAi IG on Developing Countries. Her focus is on developing HTA in emerging economies, considering the different priorities and challenges found in such countries. She is married, with two children and currently lives in Ankara, Turkey.
Isao Kamae (Japan), 2017-20
Isao Kamae is a physician, Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, The University of Tokyo, Japan, and concurrently serves as a research director for Health Economics and Policy, The Canon Institute for Global Studies (CIGS), and a research director, Meiji Institute for Global Affairs (MIGA), Meiji University, Tokyo, Japan. Also he is a visiting professor of Health Economics, Peking University, Beijing, China.
Dr. Kamae has been one of the internationally recognized leaders in value-based healthcare those twenty years, and one of the most influential scholars in public discussions on pharmacoeconomic requirements in the Japanese health insurance system, which was implemented as a pilot policy of government in 2016 – 2018. He also contributed to making an official guideline of economic evaluation for medical devices at the Japanese Ministry of Economy, Trade and Industry in 2005 – 2007.
Regarding his educational records, he was the first Japanese to be awarded a Doctor of Public Health in health decision sciences, Harvard University in 1995. is one of his major societies. He is well known as one of the founders for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia Consortium; the conference chair of the First ISPOR Asia-Pacific Conference in Kobe, Japan in 2003; the founding President of ISPOR Japan Chapter in 2005 – 2009; the first Asia-origin member on the ISPOR Board of Directors 2004-2006, and currently Chair 2016-2018, ISPOR Asia Consortium.
His international commitment has been further stretching out to the other societies beyond ISPOR since he served as co-chairs of the Local Planning Committee and the International Scientific Program Committee for HTAi Annual Meeting 2016 Tokyo, and also as a member of SMDM Asia-Pacific Advisory Council.
He has been actively collaborating with the world-class institutes, which includes School of Pharmacy, University of Washington, and Center for the Evaluation of Value and Risk in Health, Tufts Medical Center in US, The ESSEC Business School in France, and Peking University, Fudan University in China. His workshops with IQWiG, Germany on the “Efficiency Frontier” contributed to global discussions on the HTA Guidance of IQWiG in the ISPORs Athens 2008, Orlando 2009, Phuket 2010, and Beijing 2014. He gave a lecture on the Japanese-style value-based pricing and HTA at the HAS in France, the NICE in UK and the OHE in London several times since 2012. He is also invited as a member of the International Experts Advisory Committee on fair pricing at WHO, Geneva, and on innovative drugs and pricing at OECD, Paris since 2016.
His research interest highlights methodological issues on cost-benefit function and ratios theory, and its application for the Japanese-style value-based pricing. In May 2014, his article was honorably included as one of the thirty selected papers in the memorial book of Professor Bengt Jnsson, Stockholm School of Economics. He is also on the editorial board for Journal of Medical Economics. He served as the guest editor of the ISPOR official journal, Value in Health, 2nd Asia-Pacific Issue in 2009. Regarding the pilot introduction of HTA in Japan, he published a book called “HTA Workbook” in 2016, which is the first full-scale Japanese textbook alongside the methodological guideline of government.
Alric Rüther (Germany), 2016-19
Alric Rüther studied philosophy and human medicine in Munich, Budapest and Alicante (Spain) before training in Internal Medicine and Oncology at the Universities of Munich and Freiburg, and has received further training in Medical Informatics. He participated in the establishment of the German Cochrane Centre at the Institute for Medical Informatics and Biometry, University of Freiburg. Since 1999 he has been with the German Institute for Medical Documentation and Information (DIMDI), Federal Ministry of Health, and has worked to establish and build the discipline of HTA in German health care. Alric has been founder and the head of the German Agency for HTA (DAHTA) from 2001 until 2007. In 2008 Alric took over the responsibility of the Department of Health Care Quality at the Institute for Quality and Efficiency in Health Care (IQWiG). At IQWiG Alric is also responsible for the international relationship of the institute.
Alric is engaged in worldwide HTA development since 1999. With HTAi he is active since its founding. He is also engaged in INAHTA and with EUnetHTA since its beginning. Alric is member of the German Society for Medical Informatics, Biometry and Statistics (GMDS), chair of the HTA working group, and member of the German Network for Evidence-Based Medicine, chair of the field of HTA. Alric is an associate professor at the Universities of Bielefeld and Berlin, lecturing HTA.